Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.58) by 17.24 percent. This is a 42.86 percent increase over losses of $(1.19) per share from the same period last year. The company reported quarterly sales of $4.13 million which missed the analyst consensus estimate of $7.96 million by 48.15 percent. This is a 63.02 percent decrease over sales of $11.16 million the same period last year.